News and Trends 1 Feb 2023 Advancing cancer care with 3D genomics By Oxford BioDynamics Cancer care is in urgent need of effective tests to determine the best approach for personalized medicine. Practical, new solutions exploiting the power of 3D genomics are emerging. Cancer is a vastly complex, multidimensional disease marked by the uncontrolled proliferation of cells. Many intertwined layers of biological systems give rise to the […] February 1, 2023 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 27 Jul 2022 The race to uncloak cancer with liquid biopsies Until recently, cancer detection depended on invasive solid tissue sampling that didn’t provide a complete picture. An emerging crowd of biotechs is making it easier to detect and monitor cancer with liquid biopsies. The notion that a person’s blood can reveal a wealth of health information looked so shiny that the infamous blood diagnostics company […] July 27, 2022 - 10 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2018 Epigenetics Test Can Distinguish Between Huntington’s Disease Stages A study run by Oxford BioDynamics suggests that we could predict Huntington’s more easily by analyzing epigenetic changes in the patient’s DNA. Epigenetics describes the way that the expression of our genes is regulated, often influenced by environmental exposure, without changing the genetic code. Ways of modifying gene expression include attaching chemical groups to DNA […] November 8, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 Mar 2018 Oxford Firm Develops Better Test for ALS Diagnosis Oxford BioDynamics has presented data from a new diagnostic test that could help not just diagnose ALS but also help patients get a personalized treatment. Amyotrophic lateral sclerosis (ALS) is a motor neuron disease whose diagnosis comes with the hard news that most patients die merely within 3 to 5 years of diagnosis. One of […] March 20, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 24 May 2017 Top Pharma eye British Tech to Predict Response to Checkpoint Inhibitors Oxford BioDynamics will start the development of an epigenetic test to screen patients for a favorable response to anti-PD-L1 drugs. Oxford BioDynamics has announced an agreement with two of the top 10 global pharma to initiate the development of a blood-based test to predict the response to PD-L1 checkpoint inhibitors in patients with non-small cell […] May 24, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email